Physician profile
Mary Latimer
NPI 1437169638
$2,364.47
in general payments reported to CMS, 2019-2025
14 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $85.20 · 2021: $505 · 2022: $494 · 2023: $253 · 2024: $284 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $664.59 | 2019-2025 | Gamunex-C |
| Abbvie INC. | $430.51 | 2022-2025 | |
| Ucb, INC. | $370.33 | 2019-2024 | Nayzilam |
| Neurelis, INC. | $308.60 | 2021-2025 | Valtoco |
| Upsher-Smith Laboratories LLC | $164.81 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $87.62 | 2021-2022 | |
| Allergan, INC. | $86.79 | 2019-2021 | |
| Celgene Corporation | $56.44 | 2021-2022 | |
| Sk Life Science, INC. | $48.86 | 2022-2023 | |
| Biomarin Pharmaceutical INC. | $46.00 | 2022-2024 | Brineura |
| Pfizer INC. | $42.76 | 2025 | |
| Flowonix Medical Incorporated | $23.77 | 2019 | |
| Livanova USA, INC. | $16.93 | 2019 | |
| Greenwich Biosciences, INC. | $16.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Latimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.